Novavax, Inc. (FRA:NVV1)
Germany · Delayed Price · Currency is EUR | Market Cap | 1.21B -9.1% |
| Revenue (ttm) | 907.40M +20.3% |
| Net Income | 291.27M |
| EPS | 1.76 |
| Shares Out | n/a |
| PE Ratio | 4.15 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,993 |
| Average Volume | 4,347 |
| Open | 7.80 |
| Previous Close | 7.94 |
| Day's Range | 7.36 - 7.80 |
| 52-Week Range | 4.56 - 9.08 |
| Beta | n/a |
| RSI | 54.69 |
| Earnings Date | Feb 26, 2026 |
About Novavax
Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adoles... [Read more]
Financial Performance
In 2024, Novavax's revenue was $682.16 million, a decrease of -30.65% compared to the previous year's $983.71 million. Losses were -$187.50 million, -65.60% less than in 2023.
Financial numbers in USD Financial StatementsNews
Here's Why Pfizer Is Willing To Pay $500 Million For Novavax's Matrix-M
Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.
Novavax Shares Rise After Licensing Deal With Pfizer
Novavax shares are trading higher Tuesday after ... Full story available on Benzinga.com
Novavax (NVAX) Surges on Licensing Deal with Pfizer
Novavax (NVAX) Surges on Licensing Deal with Pfizer
Novavax rises after licensing deal with Pfizer
Novavax (NVAX) stock jumps as the company announces a licensing deal with Pfizer (PFE) for its Matrix-M adjuvant. Read more here.
Novavax Licenses Matrix-M Adjuvant To Pfizer For Upfront Payment Of $30 Mln
(RTTNews) - Novavax, Inc. (NVAX) announced Tuesday that it has entered into a license agreement with Pfizer, Inc. (PFE) for use of Novavax's Matrix-M adjuvant. Under the terms of the agreement, Pfizer...
Novavax Announces Entering into a License Agreement with Pfizer
Non-exclusive license allows for development by Pfizer to utilize Matrix-M ® for up to two disease areas with its products Provides Novavax with an upfront payment of $30 million with the potential fo...
Novavax enters license agreement with Pfizer for vaccine development
Novavax said on Tuesday it was entering into a licensing agreement with Pfizer to develop vaccine products for infectious diseases.
Notable Friday Option Activity: BLSH, HIMS, NVAX
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Bullish Ordinary Shares (Symbol: BLSH), where a total volume of 12,696 contracts h...
Novavax Inc at JPMorgan Healthcare Conference Transcript
Novavax Inc at JPMorgan Healthcare Conference Transcript
Novavax, Inc. (NVAX) Presents at 44th Annual J.P. Morgan Healthcare Conference
Novavax, Inc. (NVAX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Novavax, Inc. (NVAX) 44th Annual J.P.
Novavax (NVAX) Moves 11.9% Higher: Will This Strength Last?
Novavax (NVAX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in ...
CORRECTED: Why Is Novavax Stock Soaring?
Novavax Inc (NASDAQ:NVAX) shares are trading ... Full story available on Benzinga.com
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know
Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Novavax to Participate in the 44th Annual J.P. Morgan Healthcare Conference
GAITHERSBURG, Md., Jan. 7, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it will participate in the 44th Annual J.P.
Noteworthy Tuesday Option Activity: M, TEM, NVAX
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Macy's Inc (Symbol: M), where a total volume of 46,232 contracts has been traded t...
Interesting NVAX Call Options For February 2026
Investors in Novavax, Inc. (Symbol: NVAX) saw new options become available this week, for the February 2026 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NVAX...
Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know
Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Noteworthy Tuesday Option Activity: NVAX, TKO, PYPL
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Novavax, Inc. (Symbol: NVAX), where a total of 17,942 contracts have traded so far, represe...
Pfizer leads COVID-19 vaccine peers lower after revamped guidance
Pfizer (PFE) stock falls, and its COVID vaccine peers such as Moderna (MRNA) and Novavax (NVAX) also drop as the company issues a disappointing outlook. Read more here.
Why I Wouldn't Touch Novavax With a 10-Foot Pole
This stock could be a wealth destroyer in the next five years.
Here is What to Know Beyond Why Novavax, Inc. (NVAX) is a Trending Stock
Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
FDA Plans to Tighten Vaccine Approvals Weigh on These Stocks
A report that vaccine approvals could be set to get stricter is pressuring shares of major vaccine makers.
Vaccine stocks take a hit as FDA official points to link between COVID-19 vaccines and rare heart condition in young men
Memo also reportedly mentions vaccines for flu and pneumonia.
Moderna and Novavax Stocks Drop as FDA Proposes Stricter Vaccine Approvals
The FDA's top vaccine regulator outlines proposed changes to the vaccine evaluation process in an internal memo.